Home » Authors » Mark Lawson

Articles by Mark Lawson

BresaGen Merging Operations Of Stem Cell Unit With CyThera

Dec. 2, 2003

Peptech Settles License Dispute Concerning Abbott Labs' Humira

Nov. 26, 2003

Peptech Settles License Dispute Concerning Abbott Labs' Humira

Nov. 26, 2003

Financing Jump In Third Quarter; Cryptome, Pharmaxis Price IPOs

Oct. 15, 2003

Financing Jump In Third Quarter; Cryptome, Pharmaxis Price IPOs

Oct. 15, 2003

Singapore Making Biotech Waves With Vast New Biopolis Facility

Sep. 3, 2003

Singapore Making Biotech Waves With Vast New Biopolis Facility

Sep. 3, 2003

BresaGen Moving Operations To U.S. For Better Biotech Climate

Aug. 20, 2003

BresaGen Moving Operations To U.S. For Better Biotech Climate

Aug. 20, 2003

Australian Firm Defends Fees For Access To Noncoding DNA

July 16, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...